scispace - formally typeset
Journal ArticleDOI

Percutaneous closure of a gigantic patent ductus arteriosus (PDA) with pulmonary hypertension with an atrial septal defect occluder in a 35-year-old woman.

Reads0
Chats0
TLDR
A case of successful transcatheter closure of an extremely large PDA measuring minimal 24 mm with an off-label use of a 24 mm Occlutech Figulla Flex ASD Occluder is described.
Abstract
Patent ductus arteriosus (PDA) is a common form of congenital heart defects (CHD); it counts for about 5–10 % of all CHD with an incidence of one in 2,500–5,000 live births [1]. In general, volume overload of the left atrium and left ventricle caused by the shunt and pulmonary vascular disease is clear indication for closure of the defect, whereas the risk of endocarditis and aneurysm formation of the PDA is under discussion. If untreated, a large PDA will regularly lead to pulmonary hypertension, heart failure and Eisenmenger syndrome [2]. PDA was the first example of congenital heart disease to be treated by transcatheter closure, and has now become an established form of treatment for the majority of patients with very few side effects. After the initial description in 1967 by Porstmann a large variety of different devices have been described (i.e., Rashkind device, Sideris buttoned device, various PDA coils, as well as specific PDA occluder devices such as the Amplatzer PDA-occluders [3]). Nowadays, percutaneous PDA closure has proved to be safe and effective with shortand long-term results comparable to surgical closure including those cases with mild and moderate pulmonary hypertension [2]. A common problem of all commercially available devices is the inability to close PDAs larger than 14 mm diameter based on manufacturer’s recommendations. Therefore, the majority of large PDAs are often closed surgically, although there are occasional case reports of very large PDAs closed with Amplatzer VSD or ASD Occluders [4, 5]. In the following report, we describe a case of successful transcatheter closure of an extremely large PDA measuring minimal 24 mm with an off-label use of a 24 mm Occlutech Figulla Flex ASD Occluder. A 35-year-old African woman (weight 77 kg, height 167 cm, BMI 27.6) was referred to our institution with an unknown heart disease for further evaluation. Clinically, she was in apparent heart failure (New York Heart Association III), transcutaneous oxygen saturation was 96 % and auscultation revealed a pronounced second heart sound and diastolic murmur. Her exercise performance measured by a 6-min walk test was 215 m only. The ECG revealed signs of right heart pressure load, and by echocardiography the estimated right ventricle pressure was 100 mmHg. This was caused by a very large PDA. It was noteworthy that the patient was human immunodeficiency virus positive. For further hemodynamic evaluation, the patient underwent a diagnostic catheterization. The PDA had a minimal diameter of 22 mm and an ampulla of 40 mm (see Fig. 1). The systemic arterial blood pressure was 115/66 mmHg (mean 85 mmHg) and the pulmonary arterial blood pressure 107/67 mmHg (mean 85 mmHg). The calculated pulmonary vascular resistance index (PVRI) was 12.6 Wood Units and the cardiac index (CI) 5.1 l/min/m. For further testing of the pulmonary vasoreagibility, the PDA was balloon occluded with a 30-mm sizing balloon. When the balloon was stabilized in the PDA, the minimal waist measured 24 mms. Thereafter, vasoreagibility of the M. Froehle (&) N. A. Haas C. Happel K. T. Laser Department for Congenital Heart Defects, Heart and Diabetes Center, North-Rhine Westphalia, Georgstrasse 11, 32545 Bad Oeynhausen, Germany e-mail: mfroehle@hdz-nrw.de

read more

Citations
More filters
Journal Article

The effect of amlodipine on exercise-induced pulmonary hypertension and right heart function in patients with chronic obstructive pulmonary disease

TL;DR: Whether amlodipine could effectively decrease pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) and improve right heart function is investigated and may predict mortality in this disorder.
Journal ArticleDOI

Implantation of the new Nit-Occlud PDA-R device in children below 10 kilogram.

TL;DR: The Nit‐Occlud PDA‐R® device was developed and especially designed for large PDAs and its most recent experience in children with a body weight lower than 10 kg is reported.
Journal ArticleDOI

Closure of very large PDA with pulmonary hypertension: Initial clinical case-series with the new Occlutech® PDA occluder.

TL;DR: The recent experience with the new Occlutech® PDA Occluder seems suitable especially for closure of large patent ductus arteriosus sizes with elevated pulmonary artery pressure (PAH).
Journal ArticleDOI

Safety and Outcomes of Transcatheter Closure of Patent Ductus Arteriosus in Children With Pulmonary Artery Hypertension.

TL;DR: In this paper, the authors investigated whether transcatheter device closure of patent ductus arteriosus (PDA) is safe in children with pulmonary artery hypertension, and retrospectively analyzed their experience with 33 patients who underwent the procedure from January 2000 through August 2015.
Journal ArticleDOI

Outcomes of transcatheter closure of patent ductus arteriosus with the off-label use of large occluders (≥16 mm)

TL;DR: Transcatheter PDA closure with the use of large devices, which are available in Asia and Europe, is an effective and safe method, especially in adolescents and adults, however, a close follow-up of these patients is mandatory.
References
More filters
Journal ArticleDOI

ESC Guidelines for the management of grown-up congenital heart disease (new version 2010).

TL;DR: Experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition, including assessment of the risk–benefit ratio.
Journal ArticleDOI

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

TL;DR: In this first placebo-controlled trial in patients with Eisenmenger syndrome, bosentan was well tolerated and improved exercise capacity and hemodynamics without compromising peripheral oxygen saturation.

A case report and literature review

TL;DR: The Plummer-Vinson syndrome has come increasingly rare with the availabil¬ ity of iron supplements, but nonetheless it should be suspected in the setting of dysphagia and iron deficiency.
Journal ArticleDOI

The double-blind, randomized, placebo-controlled trial: Gold standard or golden calf?

TL;DR: The article examines the possibility that some of this "deviation from truth" may be the result of artifacts introduced by the masked RCT itself, and indicates that the double-blind RCT may not be objective in the realist sense, but rather is objective in a "softer" disciplinary sense.
Journal ArticleDOI

Closure of the patent ductus arteriosus with the Amplatzer PDA device: Immediate results of the international clinical trial

TL;DR: It is concluded that the ADO is safe and effective in most patients with PDA up to a diameter of 10.6 mm and further clinical trials are underway to assess its long‐term safety and efficacy.